ADMA

AI Memo

ADMA Biologics

As of 2026-09-16/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-16 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

ACAAI presentation of ASCENIV real-world evidence • 2026-11-15

Base target: $11 / p=50% prob

Biggest risk

Revenue missed the cited consensus estimate, BIVIGAM remains exposed to aggressive pricing and competition, and higher SG-001 R&D spending introduces execution risk. ASCENIV concentration means any adoption, reimbursement or manufacturing setback could materially weaken the thesis [#PR-EARNINGS-2026-09-04] [#SEC-10Q-2026-08-05].

Invalidation

Break below $7 or thesis failure.

What would change my mind?

ASCENIV is producing strong growth, favorable product mix and expanding margins while management maintains FY2026 guidance. Continued utilization gains, supportive real-world evidence and cash generation could sustain a positive rerating [#SEC-8K-2026-08-05].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-16

Base target

$11

p=50%

Bull target

$14

p=30%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Persistent BIVIGAM pricing and demand pressure
SG-001 regulatory-development progress
ASCENIV is producing strong growth, favorable product mix and expanding margins while management maintains FY2026 guidance.

BearKey bullets

ASCENIV accounts for most product revenue, creating significant single-product concentration.
BIVIGAM faces competitive supply, discounting and pricing pressure; stabilization may not persist.
Commercial biologics operations carry manufacturing, plasma-supply, quality-control and regulatory risks described in company filings.

WatchKey bullets

ACAAI presentation of ASCENIV real-world evidence

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $11 (p=50%)

Target spread vs base: +33% / -38%

Scenario probabilities

Bull Target: $14 (p=30%)Base Target: $11 (p=50%)Bear Target: $7 (p=20%)

Commentary

Recent coverage is mixed: ASCENIV growth, margin expansion and reiterated guidance are constructive, while the modest revenue miss, BIVIGAM weakness and a reported 4.8% post-earnings share decline temper enthusiasm [#PR-EARNINGS-2026-09-04]. Social, options, short-interest and employee sentiment were not supplied; their zero values indicate unavailable evidence rather than neutral readings. No usable post-print analyst revisions were provided, so missing revision data is not treated as positive evidence. The deterministic prior remains positive but supports a monitoring-oriented stance rather than a high-conviction call.

As of 2026-09-16 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Persistent BIVIGAM pricing and demand pressure
SG-001 regulatory-development progress

Scenarios

Bull Target (Scenario probability)

$14 / p=30% prob

Base Target (Scenario probability)

$11 / p=50% prob

Bear Target (Scenario probability)

$7 / p=20% prob

Analysis 2026-09-16 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.15

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-15
ACAAI presentation of ASCENIV real-world evidence
ADMA submitted an abstract covering 127 ASCENIV-treated patients for the November 2026 ACAAI meeting. The reported reductions in infection-related hospitalizations and other healthcare utilization could strengthen prescriber adoption and payer access, although conference reception and commercial conversion remain uncertain [#SEC-8K-2026-08-05].
Prob 65.00% • Move 8.00% • Priced-in 25.00%
EVENT2026-12-31
ASCENIV-led FY2026 guidance execution
Q2 revenue rose 2% year over year to $124.4 million, ASCENIV revenue increased 24% to $102.9 million, and management reiterated FY2026 revenue guidance of $530-$560 million. Sustained ASCENIV utilization and delivery against guidance are the principal near-term rerating tests [#SEC-8K-2026-08-05].
Prob 70.00% • Move 12.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Persistent BIVIGAM pricing and demand pressure
2026-12-31
BIVIGAM revenue declined sharply year over year amid competitive supply and pricing pressure, despite sequential stabilization. Failure to sustain that stabilization could offset ASCENIV growth and pressure guidance confidence [#PR-EARNINGS-2026-09-04].
Prob 40% • Move -15% • Priced-in 55%

Long-term Catalysts

Months to a year

SG-001 regulatory-development progress
2026-12-31
The prior baseline identifies a planned FDA pre-IND package by year-end 2026. This remains an early, option-like pipeline milestone rather than a proven value driver, and the 10-Q emphasizes that development timing and regulatory outcomes remain uncertain [#SEC-10Q-2026-08-05].
Prob 45% • Move 9% • Priced-in 15%

Risks

ASCENIV accounts for most product revenue, creating significant single-product concentration.
BIVIGAM faces competitive supply, discounting and pricing pressure; stabilization may not persist.
Commercial biologics operations carry manufacturing, plasma-supply, quality-control and regulatory risks described in company filings.
FY2026 guidance requires continued ASCENIV utilization growth through the second half.
Higher SG-001 research spending may dilute near-term operating leverage before clinical value is established.
Post-earnings analyst estimate and target revisions are unavailable, limiting confirmation of the market's forward view.

Peers

Symbol	Summary
AUPH	Similar market capitalization and broad biopharma classification, but its product portfolio and economics are not directly comparable with ADMA's plasma-derived biologics manufacturing and commercial model.
GHRS	Market-cap similarity does not overcome its substantially different development-stage and therapeutic profile; useful only as a broad biotechnology risk reference.
NBTX	Comparable in market capitalization but not in commercial maturity, modality, or operating model, limiting valuation relevance.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-16

Loading AI feed…

Symbol

Summary

AUPH

Similar market capitalization and broad biopharma classification, but its product portfolio and economics are not directly comparable with ADMA's plasma-derived biologics manufacturing and commercial model.

GHRS

Market-cap similarity does not overcome its substantially different development-stage and therapeutic profile; useful only as a broad biotechnology risk reference.

NBTX

Comparable in market capitalization but not in commercial maturity, modality, or operating model, limiting valuation relevance.